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GlycolysisColloidal gold nanoparticles (GNPs) are being used as drug delivery vehicles and radiation dose enhancers in
cancer therapy. Oxygen concentration in human tumours is highly heterogeneous with many regions at very
low levels of oxygen (hypoxia). A majority of tumours contain regions with oxygen pressure values of less
than 0.7% in the gas phase. The purpose of this study was to investigate how the size of the NPs affects their up-
take process in a tumour-like hypoxic environment.We usedGNPs of diameter 15, 50, and 74nm, and carried out
our experiment under 0.2% (hypoxic) and 21% (normoxic) oxygen levels usingMCF-7 and HeLa cells. Our results
showed that NPs of size 50 nm had the highest uptake following prolonged exposure to hypoxia. There was no
signiﬁcant toxicity introduced by NPs under hypoxic conditions. These ﬁndings will play a vital role in the opti-
mization of GNP-based therapeutics in cancer treatment.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).The ultimate or fundamental goal of nanoparticle (NP) based
platforms is the successful targeted delivery and monitoring of
therapeutics to tumors, while causingminimal damage to normal tissue
and side effects to the patient. Among other NPs, colloidal gold NPs
(GNPs) are being explored as a model NP-system for cancer research
due to their ability to act as both a radiosensitizer and drug carrier in
cancer therapy [1–3]. Previous studies have shown that the size of the
NP matters [4–6]. For example, GNPs of size 50 nm showed the highest
radiation dose enhancement amongNPs of sizes between 14 and 74 nm
[4]. Most of these studies were performed with properly oxygenated
(normoxic) cells. However, if we were to use these NPs effectively for
cancer therapeutic applications, it is essential to understand their
uptake behavior in a tumor-like environment, such as hypoxia.
It has been shown that low levels of oxygenation (hypoxia),
commonly present in solid tumors, protect cells from death by irradia-
tion [7]. For example, damage to DNA is created via direct ionization
from radiation, or is induced by the interaction with free radicals (e.g.erson University, 350 Victoria
5000x4115; fax: +1 416 979
hrani).
. This is an open access article underhydroxyl radical) formed by the ionization of water surrounding the
DNA. If oxygen is available, it can react with the broken ends of DNA,
thereby creating stable organic peroxides. This type of DNA damage can-
not be easily repaired. However, the damage ismore readily repairable in
the absence of molecular oxygen which would lead to less damage
following radiation or chemotherapy [8,9]. One of the primary reasons
for cancer recurrence is that these hypoxic cells can survive the treat-
ment. GNPs are being explored to overcome the resistance by these
hypoxic cells since they can be used in combined therapeutics of
radiation therapy and chemotherapy [2]. However, it is not known how
the GNP-based therapeutic response would modulate in a real tumor
where hypoxia is present. If we were to use GNPs for improved cancer
therapeutics, it is necessary to understand their behavior under hypoxia.
Amajority of solid tumors contain regionswith O2 pressure values of
less than 0.7% O2 in the gas phase, while the partial pressure of oxygen
of normal tissues is about 4–7% O2 in the gas phase [10–12]. We
conducted our experiments under 0.2% O2 level. The effect of the size
of colloidal GNPs on their cellular uptake is known under normoxic
conditions [4]. For example, colloidal GNPs of size 50 nm have the
highest cell uptake among the size range 14–74 nm. However, most of
the cancer cells in the solid tumor are hypoxic. It is not known yet
how the size of colloidal GNPs affects their cellular uptake in a real
tumor-like environment (hypoxic). Hence, the goal of this study is to in-
vestigate how the size of colloidal GNPs affects their cellular uptake in athe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Characterization of colloidal GNPs. A) Hydrodynamic diameter andUV visible peakwavelength of as-made GNPs andGNPs incubatedwith FBS supplementedmedia for duration of 24 h
under normoxic andhypoxic (0.2%O2) conditions, respectively. B–C) FTIR spectra andUVvisible spectra of naked50nmGNPs andGNPs incubatedwith FBS supplementedmedia for durationof
24 h in normoxic and hypoxic (0.2% O2) conditions, respectively.
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is an optimum NP size, we can use that particular size for an improved
outcome in therapeutic applications. For example, colloidal GNPs are
being explored as radiation sensitizers in radiation therapy and drug car-
riers in chemotherapy [13]. Hence, it is important to evaluate the size-
dependent uptake of colloidal GNPs in a real tumor-like environment, if
we were to use them for such therapeutic applications. This article
demonstrates how colloidal GNPs can be used to optimize the bio-nano
interface in a real tumor-like environment (hypoxic), since their size
and surface properties can be tailored easily.Fig. 2. Evaluation of the toxicity of GNPs. A–B) The toxicity induced byNPswasmeasured bymo
The concentration of NPs used was 0.6 nmol. All the results are the mean of three independenGNPs of diameter 15, 50, and 70 nm were synthesized using the
citrate reduction method. Colloidal GNPs were characterized by UV–
vis spectroscopy, Dynamic Light Scattering (DLS), and Transmission
Electron Microscopy (TEM) imaging. To study the effect of the hypoxic
environment on the stability of NPs, they were kept in a hypoxia
chamber for 24 h. UV–vis spectroscopy and DLS measurements were
performed to investigate the changing characteristics of the NPs. GNPs
were also incubated in the tissue culture media supplemented with
FBS (Fetal Bovine Serum) under hypoxic and normoxic conditions for
24 h. The medium can have a profound inﬂuence on particle uptakenitoring cell proliferation forMCF-7 cells in normoxic and hypoxic conditions, respectively.
t experiments ± SE.
Fig. 3.Cellular uptake of GNPs in normoxic and hypoxic cells. TheNP uptake inMCF-7 cells
whichwere exposed to hypoxic conditions for 18 h prior to NP addition. The cells exposed
to hypoxia had higher NP uptake compared to normoxic cells. NPs of diameter 50 nm had
the highest uptake under normoxic and hypoxic conditions. All results are the mean of
three independent experiments ± SE.
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culturemedia under normoxic and hypoxic conditions for 24 h. The hy-
drodynamic diameter of the GNPs increased and the peak wavelength of
the UV visible spectrum was red shifted for all three sizes (Fig. 1A). This
increase in size was due to the attachment of serum proteins in the
media onto the surface of GNPs [4,15]. However, there was no signiﬁcant
difference in the size of the GNPs incubated under hypoxic and normoxic
conditions. This was further conﬁrmed by UV visible spectroscopy and
Fourier Transform Infrared (FTIR) spectroscopy. The data is shown forFig. 4. Hyperspectral imaging of GNPs in normoxic and hypoxic cells. A-1, B-1) Dark ﬁeld imag
bright yellow dots were GNP clusters within the cells. A-2, B-2) Reﬂectance spectra from ten GGNPs of size 50 nm (Fig. 1B, C). Based on these results, we can conclude
that NPs are stable under normoxic and hypoxic conditions.
The toxicity introduced by NPs of different sizes was measured by
comparing the cell proliferation rate with and without NPs under both
normoxic and hypoxic (0.2% O2) conditions for over 42 h. HeLa and
MCF-7 cells were seeded with 0.02 × 106 cell density in 24-well dishes.
Once the cells adhered to the bottomof the dishes, a group of dishes and
a suspension of GNPs were transferred to the hypoxia chamber. After
four hours, GNPs were added to one set of dishes in the normoxic and
hypoxic chambers. One set of dishes without any added GNPs was
used as a form of control in each chamber. The concentration of GNPs
used was 0.6 nmol since the same concentration was used for our cell
uptake studies. The cell proliferation was monitored with IncuCyte™
Kinetic Live Cell Imaging System with a 2-hour time interval for 42 h.
The results are presented in Fig. 2 for the MCF-7 cell line under
normoxia and hypoxia. There was no signiﬁcant reduction in cell prolif-
eration observed for both cell lines treated with GNPs under hypoxia
and normoxia, as compared to the control where cells were not treated
with GNPs. Hence, there was no signiﬁcant induced toxicity due to the
presence of GNPs within the cells.
Previous studies have shown that the cellular uptake of NPs is size
dependent [4,16]. NPs of diameter 50 nm have the highest cell uptake
among NP sizes between 14 and 74 nm. However, this is for properly
oxygenated (normoxic) cells. The purpose of this study is to investigate
how the size of NPs affects their cellular uptake in a tumor-like (hypox-
ic) environment. For quantiﬁcation of NP uptake, cells were incubated
in the hypoxia and normoxic chambers for 18 h prior to NP addition.
The cells were then incubated with NPs for 24 h. Following incubation,
the cells were trypsinized, counted, and processed for quantiﬁcation
purposes as described in our previous studies [17]. One of the majores of GNPs localized in normoxic and hypoxic cells after 24 h of incubation with NPs. The
NP clusters localized in cells shown in images A-1, B-1, respectively.
Fig. 5.Metabolic difference between normoxic and hypoxic cells. A) A normoxic cell primarily metabolizes glucose to pyruvate followed by complete oxidation of pyruvate to CO2 in the
mitochondria generating 36 ATPs per glucose. B) A hypoxic cell has limited O2 and pyruvate is metabolized to lactate generating 2 ATPs per glucose.
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and hypoxia. Our cell uptake experiments were carried out at a concen-
tration of 0.6 nmol, and the NP uptake per cell was quantiﬁed using the
Atomic Absorption Spectroscopy (AAS) technique. As illustrated in
Fig. 3, the cells pre-exposed to hypoxia for 18 h showed higher NP
uptake as compared to normoxic cells following incubation with NPs
for 24 h (p b 0.05). In addition, NPs with diameter 50 nm showed the
highest uptake.
For qualitative analysis of NP uptake, we used the hyperspectral im-
aging technique. The dark ﬁeld images in Fig. 4 (left panel) display the
differences in cellular uptake of GNPs following a 24 hour incubation
time period in normoxic cells (top image) and in cells pre-exposed to
hypoxia (bottom image) for 18 hours, respectively. With the integrated
CytoViva hyperspectral imaging capability, reﬂectance spectra from
GNP clusters within the cell were captured as shown in Fig. 4 (right
panel). The images showed an increase in NP uptake in hypoxic cells
in contrast to normoxic cells. The images correspond to cells internal-
ized with 50 nm GNPs.
The cells develop adaptive responses to survive and proliferate under
hypoxic conditions. Under hypoxia, the ATP generation shifts from
the phosphorylation pathway in the mitochondrion to the oxygen-
independent pathway of glycolysis [18,19]. Although ATP can be generat-
ed faster with a glycolysis pathway when compared to oxidative
phosphorylation, it is less efﬁcient when comparing amounts of ATP
produced [18,20]. As illustrated in Fig. 5, normoxic cells primarily
metabolize glucose to pyruvate followed by the complete oxidation of
pyruvate to CO2. During this process, 36 ATPs are generated inmitochon-
drion per glucose molecule. In hypoxic cells, the lack of O2 results in the
activation of HIF-1 (hypoxia induced factor) pathway for the regulation
of glucose metabolism [21,22]. In hypoxic cells, glucose metabolized to
2 ATP and pyruvate leaves the cell in a form of lactate. For example, a
previous study has shown that under hypoxia, alveolar epithelial cells
maintained their energy status near that of normoxic cells by increasing
anaerobic glycolysis [22].
In this study, we investigated the effect of NP size on their uptake in
cells exposed to prolonged hypoxia (18 h in the hypoxia chamber). In
addition, we presented the stability and toxicity of NPs in a hypoxic
environment. A recent study has shown that smaller NPs (1.9 nm) had
a lower cell uptake following incubation under hypoxic conditions for
4 h [23]. In this case, the cells were exposed to hypoxic conditions for
a short period of time. Our interest was to investigate NP uptake in
cells exposed to hypoxia for a prolonged time since most of the tumor
cells at the core are exposed to similar conditions. These differences in
NP uptake can be explained by considering the extent of certain cellular
processes, such as endocytosis, exocytosis, and autophagy. It is knownthat NP cell uptake and removal takes place via an energy dependent
endo–lyso path [4,5,17]. Most of these NPs are taken up by the endocy-
tosis process [4]. Once the NPs have entered the cells, they are trapped
in the endosomes before being fused with lysosomes for processing.
Once processed, these NPs are excreted from the cell via the exocytosis
process.
Prolonged exposure of cells to hypoxic conditions could lead to
reduced nutrients and energy supply. The process called “autophagy”
is stimulated as a result of reduced nutrient availability, allowing cells
to recycle cytoplasmic components. Exocytosis is also further reduced
to conserve cellular constituents and energy [24,25]. We believe that
the exocytosis process in cells pre-exposed to prolonged hypoxia (18 h)
can be very slow, resulting in the accumulation of more NPs within
the cells over time. Our future goal is to investigate the exocytosis and
autophagy process in hypoxic cells to explain the outcome of our exper-
iment in detail.
Our study proved that NP uptakewas higher in cells thatwere under
hypoxic conditions for a lengthy period of time. The increase in NPs
within the hypoxic cells could be used to deliver a higher therapeutic
load to overcome the drug and radiation resistance. In addition, a
more aggressive combined approach can be applied since GNPs can be
used as a drug carrier and radiation dose enhancer [2]. This study
provides information as to how NP stability, toxicity, and uptake vary
in a real tumor-like hypoxic environment. Hence, these ﬁndings will
play a critical role in the use of NPs in future cancer therapeutics. Our
future goal is to investigate the efﬁcacy of such GNP-based treatment
in a hypoxic environment. Proper understanding of NP behavior and
the therapeutic response in a tumor-like environment (hypoxic) can
be used to improve the outcome of future cancer care [2]. The biocom-
patibility of GNPs would accelerate the application of such innovations
to existing therapeutic protocols in the near future.
The authors would like acknowledge the Natural Sciences and
Engineering Research Council of Canada (NSERC) and Ryerson
University for their ﬁnancial support. The authors would like to thank
Dr. Richard P Hill, Dr. Robert G. Bristow, and Dr. Bradly G Wouters at
Ontario Cancer Institute for their valuable research support and
guidance.
References
[1] B.D. Chithrani, Optimization of bio-nano interface using gold nanostructures as a
model nanoparticle system, Insci. J. 1 (2011) 136–156.
[2] S. Jelveh, B.D. Chithrani, Gold nanostructures as a platform for combinational
therapy in future cancer therapeutics, Cancer 3 (2011) 1081–1110.
[3] S. Jain, J.A. Coulter, A.R. Hounsell, K.T. Butterworth, S.J. McMahon, W.B. Hyland, M.F.
Muir, G.R. Dickson, K.M. Prise, F.J. Currell, J.M. O'Sullivan, D.G. Hirst, Cell-speciﬁc
61M. Neshatian et al. / Colloids and Interface Science Communications 1 (2014) 57–61radiosensitization by gold nanoparticles at megavoltage radiation energies, Int. J.
Radiat. Oncol. Biol. Phys. 79 (2011) 531–539.
[4] B.D. Chithrani, A.A. Ghazani, W.C.W. Chan, Determining the size and shape
dependence of gold nanoparticle uptake into mammalian cells, Nano Lett. 6
(2006) 662–668.
[5] H. Gao, W. Shi, L.B. Freund, Mechanics of receptor-mediated endocytosis, Proc. Natl.
Acad. Sci. U. S. A. 102 (2005) 9469–9474.
[6] S. Zhang, J. Li, G. Lykotraﬁtis, G. Bao, S. Suresh, Size-dependent endocytosis of
nanoparticles, Adv. Mater. 21 (2009) 419–424.
[7] B.J. Moeller, R.A. Rachel, A. Richardson, M.W. Dewhirst, Hypoxia and radiotherapy:
opportunities for improved outcomes in cancer treatment, Cancer Metastasis Rev.
26 (2007) 241–248.
[8] S. Dische, P.J. Anderson, R. Sealy, E.R. Watson, Carcinoma of the cervix-anaemia,
radiotherapy and hyperbaric oxygen, Br. J. Radiol. 56 (1983) 251–255.
[9] R. Sullivan, G.C. Paré, L.J. Frederiksen, G.L. Semenza, C.H. Graham, Hypoxia-induced
resistance to anticancer drugs is associated with decreased senescence and requires
hypoxia-inducible factor-1 activity, Mol. Cancer Ther. 7 (2008) 1961–1973.
[10] N. Chan, C.J. Koch, R.G. Bristow, Tumor hypoxia as a modiﬁer of DNA strand break
and cross-link repair, Curr. Mol. Med. 9 (2009) 401–410.
[11] R.P. Hill, R.G. Bristow, The scientiﬁc basis of radiotherapy, in: I.F. Tannock, R.P. Hill, R.
G. Bristow, L. Harrington (Eds.), The Basic Science of Oncology, McGraw-Hill Ltd.,
New York, 2005, pp. 289–321.
[12] K.R. Luoto, R. Kumareswaran, R.G. Bristow, Tumor hypoxia as a driving force in
genetic instability, Genome Integr. 4 (2013) 1–15.
[13] B.D. Chithrani, Nanoparticles for improved therapeutics and imaging in cancer
therapy, Recent Pat. Nanotechnol. 4 (2010) 171–180.
[14] D. Hühn, K. Kantner, C. Geidel, S. Brandholt, I. De Cock, S.J. Soenen, P.R. Gil, J.M.M.
Martos, K. Braeckmans, K. Müllen, G.U. Nienhaus, M. Klapper, W.J. Parak, Polymer-
coated nanoparticles interacting with proteins and cells: focusing on the sign of
the net charge, ACS Nano 7 (2013) 3253–3263.
[15] P.R. Gil, D.J. de Aberasturi, V. Wulf, B. Pelaz, P. del Pino, Y. Zhao, J. de la Fuente, I.R. de
Larramendi, T. Rojo, X.-J. Liang, W.J. Parak, The challenge to relate thephysicochemical properties of colloidal nanoparticles to their cytotoxicity, Acc.
Chem. Res. 46 (2013) 743–749.
[16] B.D. Chithrani, Intracellular uptake, transport, and processing of gold nanostruc-
tures, Mol. Membr. Biol. 27 (2010) 299–311.
[17] B.D. Chithrani, W.C.W. Chan, Elucidating the mechanism of cellular uptake and
removal of protein-coated gold nanoparticles of different sizes and shapes, Nano
Lett. 7 (2007) 1542–1550.
[18] R.A. Cairns, I.S. Harris, T.W. Mak, Regulation of cancer cell metabolism, Nat. Rev.
Cancer 11 (2011) 85–95.
[19] T.N. Seagroves, H.E. Ryan, H. Lu, B.G. Wouters, M. Knapp, P. Thibault, K. Laderoute, R.
S. Johnson, Transcription factor HIF-1 is a necessarymediator of the Pasteur effect in
mammalian cells, Mol. Cell. Biol. 21 (2001) 3436–3444.
[20] R.J. Gillies, I. Robey, R.A. Gatenby, Causes and consequences of increased glucose
metabolism of cancers, J. Nucl. Med. 49 (2008) 24S–42S.
[21] H. Takagi, G.L. King, L.P. Aiello, Hypoxia upregulates glucose transport activity
through an adenosine-mediated increase of GLUT1 expression in retinal capillary
endothelial cells, Diabetes 47 (1998) 1480–1488.
[22] A. Ouiddir, C. Planès, I. Fernandes, A. VanHesse, C. Clerici, Hypoxia upregulates
activity and expression of the glucose transporter GLUT1 in alveolar epithelial
cells, Am. J. Respir. Cell Mol. Biol. 21 (1999) 710–718.
[23] S. Jain, J.A. Coulter, K.T. Butterworth, A.R. Hounsell, S.J. McMahon, W.B. Hyland, M.F.
Muir, G.R. Dickson, K.M. Prise, F.J. Currell, D.J. Hirst, J.M. O'Sullivan, Gold nanoparticle
cellular uptake, toxicity and radiosensitisation in hypoxic conditions, Radiother.
Oncol. 110 (2014) 342–347.
[24] H. Shorer, N. Amar, A. Meerson, Z. Elazar, Modulation of N-ethylmaleimide-sensitive
factor activity upon amino acid deprivation, J. Biol. Chem. 280 (2005) 16219–16226.
[25] X. Ma, Y. Wu, S. Jin, Y. Tian, X. Zhang, Y. Zhao, L. Yu, X.-J. Liang, Gold nanoparticles
induce autophagosome accumulation through size-dependent nanoparticle uptake
and lysosome impairment, ACS Nano 5 (2011) 8629–8639.
